BALA CYNWYD, Pa.--(BUSINESS WIRE)--Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of Kythera Biopharmaceuticals, Inc. ("Kythera” or "the Company") (Nasdaq: KYTH) for possible breaches of fiduciary duty and other violations of state law in connection with the sale of the Company to Allergan plc. (“Allergan”).
Click here to learn more about the investigation http://brodsky-smith.com/955-kyth-kythera-biopharmaceuticals-inc.html, or call: 877-534-2590. There is no cost or obligation to you.
Under the terms of the transaction, Kythera shareholders will receive consideration of only approximately $75.00 for each share of Kythera stock they own. The fixed value consideration will be payable 80 percent in cash and 20 percent in new Allergan shares issued to Kythera shareholders. The investigation concerns whether the Board of Kythera breached their fiduciary duties to shareholders and whether Allergan is underpaying for Kythera. The transaction may undervalue Kythera, which has both the only approved non-surgical treatment for a double chin condition and an experimental drug for male-pattern baldness. Consequently, an analyst has placed a $85.00 per share price target on Kythera stock.
If you own common units of Kythera and wish to discuss the legal ramifications of the investigation, or have any questions, you may e-mail or call the law office of Brodsky & Smith, LLC who will, without obligation or cost to you, attempt to answer your questions. You may contact Jason L. Brodsky, Esquire or Evan J. Smith, Esquire at Brodsky & Smith, LLC, Two Bala Plaza, Suite 510, Bala Cynwyd, PA 19004 by visiting http://brodsky-smith.com/955-kyth-kythera-biopharmaceuticals-inc.html, or calling toll free 877-LEGAL-90.
Brodsky & Smith, LLC is a litigation law firm with extensive expertise representing shareholders throughout the nation in securities and class action lawsuits. The attorneys at Brodsky & Smith have been appointed by numerous courts throughout the country to serve as lead counsel in class actions and have successfully recovered millions of dollars for our clients and shareholders. Attorney advertising. Prior results do not guarantee a similar outcome.